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a health burden of global impact. In spite of the availability of an
effective vaccine for longer than two decades, about 360 million
people are chronically infected worldwide and more than one
million die each year due to HBV-associated liver pathologies.
Since HBV does not cause direct cytopathic effects under normal
infection conditions, liver injury is mostly caused by repeated
attempts of the host’s immune responses to control the infection.
Over the years, such attempts set the stage for the development
of severe liver pathologies, such as liver cirrhosis and hepatocel-
lular carcinoma.
Both virological and host factors appear to be involved in HBV
persistence. While the ability of the HBV genome to form a stable
minichromosome, the so-called covalently closed circular DNA
(cccDNA), within the hepatocyte nuclei enables the virus to per-
sist in infected hepatocytes [1], the establishment of a complex
network of virus-host interactions may permit the virus to cir-
cumvent the activation of the host antiviral responses. In this
regard, various studies have shown the potential capacity of
HBV to suppress innate immunity [2–5] and high levels of viral
antigens (HBeAg and HBsAg) have been linked to T-cell exhaus-
tion in chronically HBV-infected individuals [6,7].
Current treatment options involve the use of nucleos(t)ide
analogs (NUCs), which efﬁciently block the HBV replication path-
way by acting as inhibitors of the viral polymerase, and pegylated
IFN-a (PegIFNa) which has been shown to have both immuno-
modulatory and direct antiviral effects. Since the therapeutic con-
cepts available do not enable cccDNA eradication, the current
major aim of HBV medical treatment is to prevent the progres-
sion of liver disease by suppressing HBV replication [8]. Because
NUCs do not target cccDNA transcription [1,9], they have only
modest effects on the production of circulating viral antigens
(HBsAg, HBeAg). As a consequence, monotherapy with NUCs
can be a life commitment, during which immunological control
is rarely achieved. In contrast, reduction of serum HBsAg is moreJournal of Hepatology 20
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and seroconversion represent the closest outcome to clinical
cure, IFN-a treatment remains a valuable anti-HBV therapeutic
approach. Yet, only a minority of HBV patients responds to IFN-
a therapy and the mechanisms that drive viral antigen decline
and sustained virological responses in IFN-a-treated patients
are not entirely understood.
IFN-a has been shown to induce a complex network of intra-
cellular signaling on the infected hepatocytes. While studies in
HBV-transgenic mice have reported its capacity to accelerate
pgRNA degradation and core particle decay [11–14], recent stud-
ies performed in vitro and in HBV-infected humanized mice
showed that IFN-a can reduce the levels of both pregenomic
and subgenomic HBV-RNAs by inducing epigenetic modiﬁcations
of the histones bound to the cccDNAminichromosome [15]. Thus,
it is conceivable that IFN-a directly contributes to the decline of
viral antigen amounts (HBeAg, HBsAg) by targeting cccDNA tran-
scription. On the other hand, the effectiveness of the immune sta-
tus is known to be essential to achieve control of HBV infection
and treatment outcome may be mostly triggered by the immune
modulatory effects of PegIFNa on the innate and adaptive
immune responses.
Spontaneous resolution of viral infections typically requires
combined innate and adaptive immune responses, since the main
effectors of adaptive immunity are only activated following viral
recognition by the innate immune system, which represents a
ﬁrst line defense against pathogens [16]. In HBV infection, how-
ever, studies in chimpanzees [17] and humans [18] have sug-
gested that acute infection can be successfully controlled in the
absence of a detectable IFN-a response. Remarkably, the expres-
sion of IFN-stimulated genes (ISGs) was found to remain
unchanged in the liver of chimpanzees during the early phases
of HBV infection and spread, while a clear induction of IFN-regu-
lated genes and a large number of CD8+ T effector cells was
detected during viral clearance, emphasizing the importance of
the adaptive immune response in terminating the infection
[17]. Accordingly, the depletion of CD8+ T cells resulted in loss
of control in acute HBV infection [19].
In chronic infection, however, distinct virus-mediated mecha-
nisms may contribute to the limited effectiveness of the antiviral
response and functional alterations of both innate and adaptive13 vol. 58 j 205–209
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responses have been reported [20]. Among the mechanisms that
contribute to these functional alterations are the expression of
inhibitory receptors on the surface of HBV-speciﬁc CD8+ T cells,
such as PD-1 or CTLA-4, the suppressive action of the immuno-
suppressive cytokine IL-10 on NK cells and T cells, or the action
of regulatory T cells [16,21]. Importantly, very little information
is currently available about the effects of PegIFNa on the possible
restoration of innate and adaptive immunity in chronic HBV-
infection.
In this issue, Micco et al. [22] address this important issue and
provide important novel insights into the immunomodulatory
action of IFN-a. Indeed, one important ﬁnding of their study is
that treatment with PegIFNa leads to a signiﬁcant induction of
the cytokine IL-15 and an expansion of natural killer (CD56bright
NK) cells. Noteworthy, the expansion of functional CD56bright
NK cells correlated with the peak of virological responses, sug-
gesting a direct involvement of NK cells to the IFN-a-mediated
antiviral effects. The receptor involved in the regulation of apop-
tosis/necrosis, TRAIL, may play an important role in this setting,
since patients with a strong increase in NK cell TRAIL expression
showed signiﬁcantly greater reductions in viral load and a trend
to greater reductions in HBsAg compared to patients without an
increase in TRAIL expression. Although PegIFNa-administration
may have also directly contributed to the decline of viral loads
by suppressing viral transcription, it is worth noting that a simi-
lar association between the IFN-mediated TRAIL induction and
therapy response has been reported in HCV infection [23]. Thus,
the upregulation of TRAIL is most likely directly mediated by
IFN-a. This hypothesis would be also in line with a previous study
performed by the group of Mala Maini showing that IFN-a can
upregulate NK cell TRAIL expression 10–30-fold in vitro [24].
Treatment with PegIFNa also led to an increased IFN-c pro-
duction of NK cells. This is an important ﬁnding, since previous
studies have shown a selective impairment of NK cells obtained
from chronically HBV infected patients to produce IFN-c [25–
27]. However, in contrast to their ﬁnding regarding TRAIL, Micco
et al. did not observe a relationship between IFN-c responsive-
ness and virological outcome in the small study cohort analyzed,
possibly hinting towards a dominance of cytolytic TRAIL medi-
ated effector functions [22]. This is further supported by the ﬁnd-
ing of Dunn et al., that NK cells contribute to liver inﬂammation
by inducing TRAIL-mediated death of the hepatocytes [24]. How-
ever, in that study, NK-mediated killing of hepatocytes was not
completely blocked by TRAIL antibodies, suggesting that NK cells
may also use additional ligands to mediate liver damage and viral
control.
The mechanisms responsible for the PegIFNa mediated resto-
ration of NK cell effector functions are not fully understood. How-
ever, they are most likely not due to secondary effects, such as
viremia reduction or a decrease in the levels of the immunosup-
pressive cytokine IL-10, which has been shown to suppress IFN-c
production by NK cells in chronic HBV infection [27]. Indeed, Pep-
pa et al. did not ﬁnd a functional NK cell recovery after HBV sup-
pression and Micco et al., did not ﬁnd a decrease in the levels of
IL-10 during PegIFNa therapy. Interestingly, however, PegIFNa
treatment did lead to an increase in the expression of the activa-
tory receptor NKp46. This is an important ﬁnding, since previous
HCV infection studies have linked upregulation of NKp46 to an
increased antiviral activity, that was mediated by cytolytic and
non-cytolytic effector functions, as well as to an increased anti-206 Journal of Hepatology 201ﬁbrotic activity, that was possibly due to the higher cytotoxicity
of NKp46high cells against human hepatic stellate cells [28–30].
In contrast to the signiﬁcant PegIFNa mediated functional
augmentation of NK cells, quite different effects were observed
on T cells. Indeed, PegIFNa therapy led to a striking reduction
of CD8+ T cells, an effect that was most pronounced on predom-
inantly end-stage effector cells compared to naïve and central
memory subsets. Even more importantly, HBV-speciﬁc CD8+ T
cells remained at low frequency and no restoration of their effec-
tor functions was observed. In line with this ﬁnding, the expres-
sion levels of inhibitory markers, such as PD-1 or CTLA-4, were
not affected by IFN-a therapy. These results are in agreement
with previous studies that have analyzed the immunomodulatory
effects of IFN-a on T cells. For example, Penna et al. have recently
reported that PegIFNa does not improve early peripheral blood
HBV-speciﬁc T cell responses in HBeAg negative chronic hepatitis
[31]. Most likely, IFN-a suppresses T cell responses by its strong
antiproliferative effect. However, it is also possible that indirect
effects, such an NK cell mediated inhibition of T cells, may con-
tribute to the IFN mediated inhibition of T-cell responses. What-
ever the explanation, the elegant results obtained by Micco et al.
clearly demonstrate a differential boosting of innate and adaptive
antiviral immune responses during PegIFNa treatment [22],
whereby hinting at the limited capacities of this treatment regi-
men to restore, at least on short term, HBV-specifc T-cell
functions.
It is intriguing to note that HBV-speciﬁc CD8+ T-cell functions
could be restored, at least in part, after long-term treatment with
NUCs. In this regard, Boni et al. recently reported that HBV-spe-
ciﬁc T cells isolated from NUC-treated patients that had achieved
complete control of infection displayed efﬁcient responses after
in vitro expansion [32]. Although these cells appeared still dys-
functional ex vivo, they were comparable to those of patients
who spontaneously resolved HBV infection and were signiﬁcantly
stronger compared to those of untreated chronically infected
patients in their proliferative capacity in vitro. Thus, in contrast
to lymphocytes isolated from IFN-treated patients, efﬁcient sup-
pression of HBV infection achieved after long-term treatment
with NUCs may also favor some restoration of HBV-speciﬁc T-cell
reactivity [32]. In contrast, NUC therapy was not shown to lead to
a functional recovery of NK cells [27].
In sum, two very important conclusions can be drawn from
these studies. First, PegIFNa and NUCs have differential effects
on the innate and adaptive immune responses, and second, both
drugs have shown some capabilities to restore impaired immune
functions in chronic HBV infection. These results may have
important clinical implications since they provide the rationale
for a re-evaluation of combination therapy with PegIFNa and
NUCs in chronic HBV infection. Indeed, it should be the goal of
combination therapy to restore both arms of the immune system
to improve the possibility of complete virus control.
Combination therapy approaches that were evaluated in the
past did not show improvement of post-therapy response rates
[33,34]. It should be noted, however, that less potent NUCs were
used in those studies and both therapies were started at the same
time. The time schedule of therapy might indeed be a critical
issue in this scenario, since NUC therapy typically requires sev-
eral weeks until HBV replication is completely suppressed and
months before the HBsAg levels begin to decrease. This is in sharp
contrast to the treatment with PegIFNa, which can induce a much3 vol. 58 j 205–209
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dysfunctional during chronic HBV infection and only partially restored by either therapy. Effects on human hepatocytes are shown in the bottom row: after cccDNA-
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pression of cccDNA transcription [15] and enhancement of
TRAIL-mediated cytotoxic effector functions against the infected
hepatocytes [24]. Furthermore, combination therapy based on
the use of PegIFNa and polymerase inhibitors has already
revealed its stronger capacity in reducing the amounts of
HBcAg-positive hepatocytes and cccDNA loads, compared to
monotherapy [35,36].
Combining these clinical observations with the novel immu-
nological ﬁndings discussed above, it is tempting to speculate
that a late add-on therapy of PegIFNa to an ongoing NUC admin-
istration might be most beneﬁcial. According to this scenario,
NUC therapy would ﬁrst lead to strong suppression of viremia,
thereby assisting restoration of HBV-speciﬁc CD8+ T cells and,
subsequently, PegIFNa will be added to accelerate the decline
of circulating and intrahepatic viral antigens [37] and to allow
expansion of NK cells (Fig. 1). Importantly, the proof-of-principle
of this approach has previously been reported by Kittner et al.,
showing HBsAg seroconversion in a subgroup of patients where
PegIFNa was added late to a current NUC therapy [38]. IFN-med-
iated enhancement of NK cell activity may also augment cell
injury and compensatory hepatocyte proliferation which, in turn,Journal of Hepatology 201may increase the fraction of cccDNA-free hepatocytes and pro-
mote cccDNA destabilization [39]. Finally, the use of drugs able
to prevent (re)infection of the hepatocytes may be also envisaged
[40].
Clearly, IFN-based combination therapy concepts need to be
further investigated in larger, prospective studies, ideally
together with a comprehensive analysis of both arms of the
immune system. It is also conceivable that additional strategies
will be needed to achieve efﬁcient restoration of the adaptive
immunity in chronically HBV infected patients [41]. For example,
a more potent restoration of HBV speciﬁc T-cell functions may be
achieved by the additional blockade of inhibitory receptors
[42,43]. Also of particular interest are new approaches based on
T-cell receptor gene transfer [44,45] or the application of chime-
ric antigen receptors [46].
Nonetheless, numerous studies have shown that IFN response
is achieved only in a minority of treated patients. Although the
existence of distinct host polymorphisms able to predict virolog-
ical response to IFN-based therapy has not yet been elucidated
[32], further investigation of the molecular mechanisms involved
in IFN response in chronically HBV infected patients will be indis-
pensable, while the development of therapeutic strategies aiming3 vol. 58 j 205–209 207
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at inducing stronger suppression of both HBV replication and
antigen productivity is warranted. The novel insights into diver-
gent immunomodulatory effects of IFN are an important step in
reﬁning treatment strategies with the ultimate goal to com-
pletely eradicate HBV.Conﬂict of interest
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